← Back to Clinical Trials
Recruiting Phase 3 NCT05842330

Benefits of ADHD Treatment in Detained People

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition ADHD
Sponsor Stéphanie Baggio
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-01-01
Completion 2026-10-30
Interventions
ConcertaPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.

Eligibility Criteria

Inclusion Criteria: * age between 18 and 65 * good command of French * stay in prison approx. 4 months at eligibility visit * endorsing clinical diagnostic criteria for DSM-5 ADHD * providing written informed consent Exclusion Criteria: * presence of an acute uncontrolled comorbid psychiatric disorder * medical contraindication to stimulant prescription * potential adverse interaction with another medication * already receive ADHD treatment

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE ADHD TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}